These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 25312684

  • 1. A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma.
    Chawla SP, Chua VS, Hendifar AF, Quon DV, Soman N, Sankhala KK, Wieland DS, Levitt DJ.
    Cancer; 2015 Feb 15; 121(4):570-9. PubMed ID: 25312684
    [Abstract] [Full Text] [Related]

  • 2. First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial.
    Chawla SP, Papai Z, Mukhametshina G, Sankhala K, Vasylyev L, Fedenko A, Khamly K, Ganjoo K, Nagarkar R, Wieland S, Levitt DJ.
    JAMA Oncol; 2015 Dec 15; 1(9):1272-80. PubMed ID: 26378637
    [Abstract] [Full Text] [Related]

  • 3. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S, Tucci A, Villani G, Carteni G, Spadini N, Palumbo R.
    Anticancer Res; 2000 Dec 15; 20(1B):485-91. PubMed ID: 10769710
    [Abstract] [Full Text] [Related]

  • 4. A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.
    Ganjoo KN, Cranmer LD, Butrynski JE, Rushing D, Adkins D, Okuno SH, Lorente G, Kroll S, Langmuir VK, Chawla SP.
    Oncology; 2011 Dec 15; 80(1-2):50-6. PubMed ID: 21625179
    [Abstract] [Full Text] [Related]

  • 5. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
    Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock G, Hameed MR, Shah GD, Qin A, Shahir A, Cronier DM, Ilaria R, Conti I, Cosaert J, Schwartz GK.
    Lancet; 2016 Jul 30; 388(10043):488-97. PubMed ID: 27291997
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic study of aldoxorubicin in patients with solid tumors.
    Mita MM, Natale RB, Wolin EM, Laabs B, Dinh H, Wieland S, Levitt DJ, Mita AC.
    Invest New Drugs; 2015 Apr 30; 33(2):341-8. PubMed ID: 25388939
    [Abstract] [Full Text] [Related]

  • 7. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
    Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE.
    Clin Cancer Res; 2002 Mar 30; 8(3):718-28. PubMed ID: 11895901
    [Abstract] [Full Text] [Related]

  • 8. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.
    Mamot C, Ritschard R, Wicki A, Stehle G, Dieterle T, Bubendorf L, Hilker C, Deuster S, Herrmann R, Rochlitz C.
    Lancet Oncol; 2012 Dec 30; 13(12):1234-41. PubMed ID: 23153506
    [Abstract] [Full Text] [Related]

  • 9. Aldoxorubicin for the treatment of soft tissue sarcoma.
    Sachdev E, Sachdev D, Mita M.
    Expert Opin Investig Drugs; 2017 Oct 30; 26(10):1175-1179. PubMed ID: 28846045
    [Abstract] [Full Text] [Related]

  • 10. A dose escalation study of pegylated liposomal Doxorubicin (caelyx) in combination with capecitabine (xeloda) in patients with refractory solid tumors.
    Maltezos E, Amarantidis K, Trichas M, Vasiliadis M, Toromanidou M, Chatzaki E, Karayiannakis A, Tsaroucha A, Romanidis K, Kakolyris S.
    Oncology; 2005 Oct 30; 69(6):463-9. PubMed ID: 16374040
    [Abstract] [Full Text] [Related]

  • 11. Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
    Chow WA, Synold TW, Tetef ML, Longmate J, Frankel P, Lawrence J, Al-Khadimi Z, Leong L, Lim D, Margolin K, Morgan RJ, Raschko J, Shibata S, Somlo G, Twardowski P, Yen Y, Doroshow JH.
    Cancer Chemother Pharmacol; 2004 Sep 30; 54(3):241-8. PubMed ID: 15173955
    [Abstract] [Full Text] [Related]

  • 12. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
    Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, Radford JA, Van Glabbeke MM, Kirkpatrick A, Hogendoorn PC, Blay JY, European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
    J Clin Oncol; 2007 Jul 20; 25(21):3144-50. PubMed ID: 17634494
    [Abstract] [Full Text] [Related]

  • 13. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan J, Hohenberger P, Krarup-Hansen A, Alcindor T, Marreaud S, Litière S, Hermans C, Fisher C, Hogendoorn PC, dei Tos AP, van der Graaf WT, European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Lancet Oncol; 2014 Apr 20; 15(4):415-23. PubMed ID: 24618336
    [Abstract] [Full Text] [Related]

  • 14. Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study.
    Gelderblom H, Blay JY, Seddon BM, Leahy M, Ray-Coquard I, Sleijfer S, Kerst JM, Rutkowski P, Bauer S, Ouali M, Marreaud S, van der Straaten RJ, Guchelaar HJ, Weitman SD, Hogendoorn PC, Hohenberger P.
    Eur J Cancer; 2014 Jan 20; 50(2):388-96. PubMed ID: 24215845
    [Abstract] [Full Text] [Related]

  • 15. First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours.
    Schöffski P, Delord JP, Brain E, Robert J, Dumez H, Gasmi J, Trouet A.
    Eur J Cancer; 2017 Nov 20; 86():240-247. PubMed ID: 29055839
    [Abstract] [Full Text] [Related]

  • 16. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
    Choy E, Flamand Y, Balasubramanian S, Butrynski JE, Harmon DC, George S, Cote GM, Wagner AJ, Morgan JA, Sirisawad M, Mani C, Hornicek FJ, Duan Z, Demetri GD.
    Cancer; 2015 Apr 15; 121(8):1223-30. PubMed ID: 25536954
    [Abstract] [Full Text] [Related]

  • 17. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D, Frassineti GL, Zoli W, Milandri C, Tienghi A, Ravaioli A, Gentile A, Salzano E.
    Semin Oncol; 1996 Oct 15; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [Abstract] [Full Text] [Related]

  • 18. Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001).
    Hartmann JT, Mayer F, Schleicher J, Horger M, Huober J, Meisinger I, Pintoffl J, Käfer G, Kanz L, Grünwald V, German sarcoma group.
    Cancer; 2007 Aug 15; 110(4):861-6. PubMed ID: 17599772
    [Abstract] [Full Text] [Related]

  • 19. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
    Lee SH, Chang MH, Baek KK, Han B, Lim T, Lee J, Park JO.
    Oncology; 2011 Aug 15; 80(3-4):257-61. PubMed ID: 21734417
    [Abstract] [Full Text] [Related]

  • 20. Phase I-II trial of high-dose epirubicin in patients with lymphoma.
    Case DC, Gams R, Ervin TJ, Boyd MA, Oldham FB.
    Cancer Res; 1987 Dec 01; 47(23):6393-6. PubMed ID: 3479245
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.